122357-96-4

Basic information

• Product Name: Methyl 4-(diethylcarbaMoyl)benzoate
• Synonyms: Methyl 4-(diethylcarbaMoyl)benzoate
• CAS NO: 122357-96-4
• Molecular Formula: C₁₃H₁₇NO₃
• Molecular Weight: 235.27898
• Mol File: 122357-96-4.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Methyl 4-(diethylcarbaMoyl)benzoate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 4-(diethylcarbaMoyl)benzoate(122357-96-4)
• EPA Substance Registry System: Methyl 4-(diethylcarbaMoyl)benzoate(122357-96-4)

Safety Data

• Hazardous Substances Data: 122357-96-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research and Drug Development:
Methyl 4-(diethylcarbamoyl)benzoate is used as a chemical intermediate for the synthesis of pharmacologically active molecules, contributing to the development of new drugs with therapeutic potential.
Used in Central Nervous System Disorders and Neurodegenerative Diseases:
Methyl 4-(diethylcarbamoyl)benzoate is used as a potential drug candidate for the treatment of central nervous system disorders and neurodegenerative diseases, due to its ability to target specific biological pathways and molecular targets.
Used in the Design and Exploration of Drug Candidates:
Methyl 4-(diethylcarbamoyl)benzoate is used as a valuable component in the design and exploration of potential drug candidates, facilitating the discovery of novel pharmaceutical agents with therapeutic potential.

Upstream product

• 201230-82-2 carbon monoxide 
• 77726-96-6 methyl 4-(3,3-diethyltriaz-1-en-1-yl)benzoate 
• 1679-64-7 Monomethyl terephthalate 
• 7377-26-6 4-Methoxycarbonylbenzoyl chloride 
• 109-89-7 diethylamine 
• 79-37-8 oxalyl dichloride 

Downstream Products

• 122382-43-8 4-Diethylcarbamoyl-isophthalic acid dimethyl ester 
• 122357-99-7 4-Diethylcarbamoyl-phthalic acid dimethyl ester 
• 1571-08-0 methyl 4-formylbenzoate 
• 1620210-47-0 methyl 4-(diethylcarbamoyl)-3-(1-phenylethyl)benzoate 
• 68453-55-4 methyl 4-((diethylamino)methyl)benzoate 
• 71888-24-9 4-(diethylaminocarbonyl)benzoic acid 

Relevant articles and documents

Discovery of Novel Thiophene-arylamide Derivatives as DprE1 Inhibitors with Potent Antimycobacterial Activities

In this study, we report the design and synthesis of a series of novel thiophene-arylamide compounds derived from the noncovalent decaprenylphosphoryl-β-d-ribose 2′-epimerase (DprE1) inhibitor TCA1 through a structure-based scaffold hopping strategy. Systematic optimization of the two side chains flanking the thiophene core led to new lead compounds bearing a thiophene-arylamide scaffold with potent antimycobacterial activity and low cytotoxicity. Compounds 23j, 24f, 25a, and 25b exhibited potent in vitro activity against both drug-susceptible (minimum inhibitory concentration (MIC) = 0.02-0.12 μg/mL) and drug-resistant (MIC = 0.031-0.24 μg/mL) tuberculosis strains while retaining potent DprE1 inhibition (half maximal inhibitory concentration (IC50) = 0.2-0.9 μg/mL) and good intracellular antimycobacterial activity. In addition, these compounds showed good hepatocyte stability and low inhibition of the human ether-à-go-go related gene (hERG) channel. The representative compound 25a with acceptable pharmacokinetic property demonstrated significant bactericidal activity in an acute mouse model of tuberculosis. Moreover, the molecular docking study of template compound 23j provides new insight into the discovery of novel antitubercular agents targeting DprE1.

Diaryl 2- amide-substituted thiophene imide ester compound as well as preparation method and application thereof (by machine translation)

The invention also discloses a 2 - synthesis method thereof, and an application of the compound as an antibacterial agent, in the phthisis-caused by the bacterium, in particular to the, mycobacterium-induced infectious disease (especially (Tuberculosis,TB), mycobacterium- induced mycobacterium, tuberculosis), and (I) the invention, specifically relates to a pharmaceutical composition containing the compound of the present invention or, a R pharmaceutical composition comprising the compound of the present invention. 1 , R2 , R3 , R4 , R5 As described Y in the present invention. as described in the specification, the present invention is directed, to the preparation of novel compounds, having an anti-mycobacterial activity as potential, new drug (s) for the treatment (TB) or preventative treatment of infectious diseases, consisting of M. tuberculosis, in particular phthisis- caused by tubercular mycobacteria, while being useful in overcoming the problems associated with drug resistance. (by machine translation)

N2 extrusion and co insertion: A novel palladium-catalyzed carbonylative transformation of aryltriazenes

A novel procedure for the replacement of N2 with CO of aryltriazenes has been developed. Aryltriazenes were converted to the corresponding arylamides catalyzed by 1 mol % of PdCl2/P(o-Tol)3 under CO pressure. In this process, aryldiazonium salts were generated in the presence of 40 mol % of MeSO3H. Nitrogen was released from the substrates and CO formally inserted. Aryl bromides, iodides, alkynes, and free hydroxyl groups can be tolerated in this transformation.

Rapid Access to 3-Aminoindazoles from Tertiary Amides

A two-step synthesis of structurally diverse 3-aminoindazoles from readily available starting materials was developed. This sequence includes a one-pot synthesis of aminohydrazones through chemoselective Tf2O-mediated activation of tertiary ami

A practical in situ generation of the schwartz reagent. reduction of tertiary amides to aldehydes and hydrozirconation

A new, highly efficient in situ protocol (Cp2ZrCl2/LiAlH(OBu-t)3) is described for the generation of the Schwartz reagent which provides a convenient method for the amide to aldehyde reduction and the regioselective hydrozirconation-iodination of alkynes and alkenes. Highlighted are chemoselective reductions of benzamides derived by directed ortho metalation (DoM) chemistry, allowing the synthesis of valuable 1,2,3-substituted benzaldehydes. The single-step, three-component process proceeds in a very short reaction time, shows excellent functional group compatibility, and uses inexpensive and long-storage stable reducing reagents.

Spiro compounds or salts thereof and preventives/remedies for autoimmune diseases and AP-1 inhibitors containing the same

The spiro compounds of the present invention represented by the general formula: wherein A, R2, R3, R4, R5, R6and n are as defined in the specification, exhibit an AP-1 activity inhibitory action and, based on the AP-1 inhibitory action, suppresses the expression of a wide variety of genes and are useful as an agent for treating and preventing autoimmune diseases with lessoned side reactions.